Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02750631
Other study ID # 6938
Secondary ID
Status Completed
Phase N/A
First received April 20, 2016
Last updated August 28, 2017
Start date April 2014
Est. completion date July 2017

Study information

Verified date August 2017
Source New York State Psychiatric Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Depressed patients miss a night of sleep (Wake Night), then sleep at predetermined times ending at their desired sleep time. Beginning the morning following their Wake Night, patients sit in front of a bright light, continuing morning bright light and specified sleep time for six weeks with weekly visits measuring depressive symptoms.


Description:

Nonpsychotic, nonbipolar, physically healthy depressed patients keep sleep, mood and energy logs for a week, complete the Morningness-Eveningness Questionnaire (measuring "morningness" and "eveningness") and determine the time patients want to sleep. Patients then miss a night of sleep and subsequently are allowed later and later sleep times until patients are sleeping at their desired time. Beginning the morning following their Wake Night, patients sit in front of bright lights at their intended wake-up time for the next six weeks and once their allowed sleep time is their intended sleep time, patients also continue to only be allowed to sleep between those times (e.g., 11 p.m. to 7 a.m.). Daily sleep, energy and mood logs and activity monitoring are maintained throughout with weekly clinician ratings. In additional, daily telephone check ins occur during the first week following the Wake Night both to be sure the patient is following the protocol and to obtain symptom ratings. Saliva to be measured for melatonin is collected prior to and following sleep adjustment.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 2017
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- major depressive disorder or persistent depressive disorder or unspecified depressive disorder

- physically healthy

- patients over age 60 need primary care physician's approval, electrocardiogram and Mini Mental Status Examination

Exclusion Criteria:

- medically unstable condition

- bipolar disorder

- current (past six months) substance use disorder

- significant suicide risk

- need for hospitalization

- history of psychosis

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Triple Therapy
The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance

Locations

Country Name City State
United States New York State Psychiatric Institute New York New York

Sponsors (1)

Lead Sponsor Collaborator
New York State Psychiatric Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 17-item Hamilton Rating Scale for Depression The Hamilton Rating Scale for Depression is a standard clinician scored rating of depressed mood and the symptoms commonly associated with clinical depression 1 week
See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Recruiting NCT05570110 - Enoxolone in Major Depression - Biomarker-outcome Relationship Phase 1/Phase 2
Completed NCT02530164 - Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression N/A
Completed NCT00964054 - Depression Outcomes Study of Exercise Phase 1
Completed NCT01447602 - A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior Phase 3
Completed NCT00517387 - The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression Phase 3
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Recruiting NCT05894980 - How to Reduce Suicidal Thoughts and Impulsivity in Depression N/A
Terminated NCT04712968 - Efficacy of Daylight as Adjunctive Treatment in Patients With Depression N/A
Enrolling by invitation NCT04717921 - Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
Recruiting NCT03358056 - Effects of Mindfulness Based Cognitive Therapy on Emotional Processing N/A
Recruiting NCT03711019 - Efficacy of Convulsive Therapies During Continuation N/A
Completed NCT02104232 - Thinking Healthy Program - Peer Delivered, India (THPP-I) N/A
Completed NCT02111915 - Thinking Healthy Program - Peer Delivered (Pakistan) N/A
Terminated NCT01219686 - EScitalopram PIndolol ONset of Action Phase 2/Phase 3
Completed NCT00158990 - Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression. Phase 3
Completed NCT01049347 - Amitriptyline and Paroxetine Treatment of Major Depression Phase 3
Completed NCT03268434 - Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care N/A
Completed NCT01880957 - PET and MRI Brain Imaging of Bipolar Disorder N/A
Completed NCT04420793 - Voice Changes During ECT